Publiziert in: Marktpuls, Unternehmen
Frei

Ypsomed announces share repurchase of up to CHF 150 million Montag, 02. März 2026 - 07:12

LOG_Ypsomed.png

Ad hoc announcement pursuant to Art. 53 LR

Ypsomed announces share repurchase of up to CHF 150 million 

Burgdorf, 02.03.2026, 07:00 a.m. – Ypsomed's (SIX: YPSN) Board of Directors has approved a share repurchase program of up to CHF 150 million at a fixed price of CHF 300.00 per share. As part of the program, CHF 100 million worth of shares have been repurchased from the main shareholder, who participated in proportion to his ownership in the company. In addition, the company will initiate a public repurchase offer for up to CHF 50 million, commencing on 3 March 2026.  

Newsletter-YPS_BUI_Headquarter_Burgdorf_Front.jpg

The Board of Directors of Ypsomed Holding AG has authorized the repurchase of up to 500 000 shares of the company's outstanding common stock, for a maximum total of CHF 150 million. This represents approximately 3.66% of the share capital and voting rights of Ypsomed currently registered in the commercial register (2.44% from the main shareholder and up to 1.22% through the public repurchase offer). The share repurchase aligns with Ypsomed's commitment to delivering value to its shareholders. 

"Through this share repurchase program, we are returning capital to our shareholders while optimizing our capital structure. The program highlights our view of our stock as an appealing investment, reflecting our strong confidence in Ypsomed's long-term strategy and financial stability. Importantly, our expansion strategy will not be affected by this share buyback," stated Simon Michel, Chief Executive Officer. 

Repurchases from the main shareholder 

Repurchases from the main shareholder have resulted in the acquisition of shares totalling CHF 100 million from Dr. h.c. Willy Michel, who participated in proportion to his approximately two-thirds stake in the company. This one-time repurchase involves 333 333 shares at a price of CHF 300.00, with the agreement signed and effective Friday, 27 February 2026. As part of the share buyback arrangement with the main shareholder, Dr. h.c. Willy Michel has committed not to tender any registered shares in connection with the public buyback offer. 

Public repurchase offer 

The company is offering to repurchase up to 166 667 shares at a fixed price of CHF 300.00 per share, worth up to CHF 50 million. The buyback notice is linked below this message and is valid from Tuesday, 3 March 2026, to Tuesday, 17 March 2026, 12 p.m. CET. If the number of registered shares tendered exceeds the amount offered, the shares will be repurchased from the tendering shareholders on a pro rata basis, i.e., the tenders will be reduced proportionally. The results of the public share repurchase will be announced as an ad hoc announcement on Wednesday, 18 March 2026. The payment of the net buyback price and the delivery of the registered shares will take place on Friday, 20 March 2026. 

Capital Contribution Reserves will be utilized for all repurchases, to exempt the share repurchases from withholding tax. Ypsomed has mandated UBS AG to execute the buyback offer. 

Cancellation of shares 

Ypsomed plans to cancel the shares that have been repurchased. 

Buyback notice

Buyback notice English
Buyback notice German
Buyback notice French 

Contact
Sam Ghezelbash, Head of M&A and IR, Ypsomed Holding AG
+41 76 228 51 45, sam.ghezelbash@ypsomed.com

This communication and the media material can be found at Media services - Ypsomed.

Ypsomed Group

Ypsomed is the leading developer and manufacturer of injection systems for the self-administration of liquid medication. As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Backed by a proven track record, Ypsomed offers the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions. Ypsomed is headquartered in Burgdorf, Switzerland, and operates a global network of manufacturing facilities. More than 2 000 employees worldwide are committed every day to making selfcare simpler and easier. 

Ypsomed AG, Brunnmattstrasse 6, 3401 Burgdorf
info@ypsomed.com, www.ypsomed.com